
    
      Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24
      weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA
      <50 copies/mL at entry
    
  